Why the study?
Sacubitril/valsartan preserves renal function better than RAS inhibitors in HFrEF, but evidence on its renoprotective impact and underlying mechanisms in cardiorenal syndrome needed comprehensive review.
Do angiotensin receptor-neprilysin inhibitors improve renal function in patients with cardiorenal syndrome?
Comparison
ARNIs (sacubitril/valsartan) vs RAS inhibitors
Design
Review of pre-clinical and clinical studies
Authors
Loading...
May support ARNI consideration for renoprotection in cardiorenal syndrome; leaves open need for dedicated RCTs before practice change.
Do angiotensin receptor-neprilysin inhibitors improve renal function in patients with cardiorenal syndrome?
This review highlights the potential of ARNIs, particularly sacubitril/valsartan, to provide renoprotective effects in patients with cardiorenal syndrome.
Rahman et al. (2025) studied this question.